This record contains data related to article "Distribution of pamiparib, a novel inhibitor of poly(ADP-ribose)-polymerase (PARP), in tumor tissue analyzed by multimodal imaging" Pamiparib is a potent and selective oral PARP1/2 inhibitor (PARPi). Pamiparib has good bioavailability and showed greater cytotoxic potency and similar DNA-trapping capacity compared to olaparib. It is not affected by ATP-binding cassette transporters. Consequently, pamiparib may be useful in overcoming drug resistance caused by poor drug distribution in tumor due to overexpression of these efflux pump [1]. Mass spectrometry imaging (MSI) is a powerful technology that allows to study drugs distribution in tissues while maintaining spatial information [2]. Here, MSI was applied to visualize pamiparib in tumor in combination with spatial metabolomics and lipidomics, LC-MS/MS analysis, immunofluorescence analysis, and histological staining to gain a comprehensive understanding of how pamiparib is distributed. The results show that pamiparib was evenly distributed in ovarian tumor models, including those that overexpress P-glycoprotein (P-gp). In contrast, olaparib was not detected by MSI in any of the analyzed tumors, despite the comparable sensitivity of the analytical method. This difference in tumor distribution was confirmed by LC-MS/MS analysis.